First of three phase 3 cancer pain trials shows disappointing results
the ONA take:
Patients with advanced cancer often do not attain adequate pain relief from optimized chronic opioid therapy or experience unacceptable opioid side effects.
Researchers believe that cannabinoid therapy as a co-analgesic may provide pain relief beyond opioid therapy. In a phase 3 trial for the investigational product Sativex, a cannabinoid medicine, topline results show that the primary end point of demonstrating a statistically significant difference from placebo was not achieved.
A total of 399 patients were recruited at clinical sites in the United States, Mexico, and Europe for this randomized double-blind placebo-controlled parallel-group study.
The trial evaluated Sativex at a dose range of 3 to 10 sprays/day over a 5-week period with an additional stabilization period of 5 to 14 days at the beginning of the trial and a 1-week follow-up at the end of the trial.
Participants received Sativex or placebo as adjunctive treatment to optimized chronic opioid therapy and remained on stable doses of their background opioid therapy during the study.
This is the first of three phase 3 trials of this investigational product, and although the researchers are disappointed that the primary end point was not achieved, they are optimistic that results from the other studies will support filing a New Drug Application with the FDA.
Sativex is currently approved in 27 countries outside the United States for the treatment of spasticity due to multiple sclerosis. A request for Special Protocol Assessment has been submitted to the FDA for a proposed single phase 3 study in this indication.
Patients with advanced cancer often do not attain adequate pain relief from optimized chronic opioid therapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|